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PCLINICAL RESEARCH Acute Myocardial Infarction
Efficacy and Safety of Immediate Angioplasty
Versus Ischemia-Guided Management After
Thrombolysis in Acute Myocardial Infarction
in Areas With Very Long Transfer Distances
Results of the NORDISTEMI (NORwegian study on
DIstrict treatment of ST-Elevation Myocardial Infarction)
Ellen Bøhmer, MD,* Pavel Hoffmann, MD, PHD,† Michael Abdelnoor, PHD,‡
Harald Arnesen, MD, PHD,§ Sigrun Halvorsen, MD, PHD*
Oslo and Lillehammer, Norway
Objectives The goal of this study was to compare a strategy of immediate transfer for percutaneous coronary intervention
(PCI) with an ischemia-guided approach after thrombolysis in patients with very long transfer distances to PCI.
Background Thrombolysis remains the treatment of choice in ST-segment elevation myocardial infarction (STEMI) when pri-
mary PCI cannot be performed within 90 to 120 min. The optimal treatment after thrombolysis is still unclear.
Methods A total of 266 patients with acute STEMI living in rural areas with more than 90-min transfer delays to PCI were
treated with tenecteplase, aspirin, enoxaparin, and clopidogrel and randomized to immediate transfer for PCI or
to standard management in the local hospitals with early transfer, only if indicated for rescue or clinical deterio-
ration. The primary outcome was a composite of death, reinfarction, stroke, or new ischemia at 12 months, and
analysis was by intention to treat.
Results The primary end point was reached in 28 patients (21%) in the early invasive group compared with 36 (27%) in
the conservative group (hazard ratio: 0.72, 95% confidence interval: 0.44 to 1.18, p  0.19). The composite of
death, reinfarction, or stroke at 12 months was significantly reduced in the early invasive compared with the
conservative group (6% vs. 16%, hazard ratio: 0.36, 95% confidence interval: 0.16 to 0.81, p  0.01). No signifi-
cant differences in bleeding or infarct size were observed.
Conclusions Immediate transfer for PCI did not improve the primary outcome significantly, but reduced the rate of death, reinfarc-
tion, or stroke at 12 months in patients with STEMI, treated with thrombolysis and clopidogrel in areas with long
transfer distances. (Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction; NCT00161005).
(J Am Coll Cardiol 2010;55:102–10) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.007m
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ccepted August 4, 2009.yocardial infarction (STEMI), if it can be delivered in a
imely manner by an experienced team (1,2). However, in
ural areas with long transfer distances to PCI centers,
rimary PCI cannot be performed within the recommended
ime limits and thrombolysis remains the treatment of
See page 111
hoice (2). The optimal treatment after thrombolysis is still
nclear. Several studies have shown a beneficial effect of
arly transfer for coronary angiography and PCI if indicated,
ut the exact timing of angiography, the adjunctive anti-
hrombotic medication, and the strategy for the conservative
roup in these studies have differed (3–7). Furthermore, few
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January 12, 2010:102–10 Management of Acute Myocardial Infarction in Rural Areasf the studies have included patients with very long transfer
istances. Long transfer distances to PCI might increase the
eed for early transfer in case of rescue indication, but also
ight increase the risk of complications.
Because more data are needed on the effects of early PCI
fter thrombolytic treatment for STEMI, we designed
ORDISTEMI (NORwegian study on DIstrict treatment
f ST-Elevation Myocardial Infarction) (8). The goal of
his trial was to compare the effects of 2 reperfusion
trategies both applied after full-dose thrombolysis: to
ransfer all patients immediately for PCI or to manage the
atients more conservatively with an ischemia-guided strat-
gy. The study was performed in a rural area with long
ransfer distances to PCI and widespread use of pre-hospital
hrombolysis.
ethods
he design features of NORDISTEMI have been pub-
ished previously (8).
atient selection. The study was conducted in 5 com-
unity hospitals in the southeastern part of Norway, with
he interventional facility located at Oslo University
ospital, Ulleval. Enrollment was performed between
ebruary 2005 and April 2008 in a pre-defined area with
00- to 400-km transfer distances to PCI and a well-
stablished system for pre-hospital thrombolysis. Table 1
hows the inclusion and exclusion criteria. The protocol
as approved by the Regional Committee for Medical
esearch Ethics, and all patients provided written, in-
ormed consent in accordance with the revised Declara-
ion of Helsinki.
tudy design. All patients received standard weight-
djusted dose tenecteplase, aspirin 300 mg orally, and
noxaparin 30 mg intravenously followed by a subcutaneous
ose of 1 mg/kg repeated every 12 h up to hospital discharge
tudy Inclusion and Exclusion CriteriaTable 1 Study Inclusion and Exclusion Criteria
Inclusion criteria
1. Age 18–75 yrs
2. Symptoms of myocardial infarction present for 6 h
3. ECG indicative of an acute STEMI: 2 mm ST-segment elevation
in 2 contiguous precordial leads or 1 mm ST-segment elevation
in 2 contiguous extremity leads or new left bundle branch block
4. Expected time delay from first medical contact to PCI 90 min
5. Receiving thrombolytic treatment with tenecteplase
6. Informed consent for participation
Exclusion criteria
1. Standard exclusion criteria for tenecteplase
2. Cardiogenic shock or serious arrhythmias at randomization
3. Pregnancy
4. Known serious renal failure (serum creatinine 250 mmol/l)
5. Other diseases with life expectancy 12 months
6. Psychiatric disease, mental retardation, dementia, drug abuse, alcoholism,
or conditions that can severely reduce compliancew
CG  electrocardiogram; PCI  percutaneous coronary intervention; STEMI  ST-segment
levation myocardial infarction.r revascularization for a maxi-
um of 7 days. All patients also
eceived clopidogrel 300 mg on
he first day (9).
Eligible patients were asked
or participation at the same time
s thrombolysis was given, and
andomized in a 1:1 way to an
arly invasive or a conservative
trategy. Permuted block ran-
omization stratified by site, and
ealed envelopes containing treat-
ent modality according to ran-
om numbers were used. The
andom allocation sequence was
enerated at the Center for Clin-
cal Research, Oslo University
ospital, Ulleval.
Patients assigned to the early invasive strategy were
ransferred to the PCI center as soon as possible after
hrombolysis, for immediate coronary angiography and
ngioplasty of the infarct-related artery if indicated
50% diameter stenosis). The choice of stent type and
se of glycoprotein IIb/IIIa inhibitor were at the opera-
or’s discretion. Likewise, referral for surgery in case of
eft main coronary artery disease or serious 3-vessel
isease was left to the judgment of the operator.
Patients assigned to conservative treatment were ad-
itted to (in case of pre-hospital thrombolysis) or kept in
he community hospitals for continued care, with referral
or urgent angiography if persistent chest pain and 50%
eduction of ST-segment elevation 60 min after initia-
ion of thrombolysis (rescue indication) or hemodynamic
nstability. Referral for early coronary angiography was
ecommended if the patient had spontaneous recurrent
schemia with or without electrocardiogram (ECG) changes,
r if signs of ischemia (chest pain, significant ST-
egment changes, hypotension, or ventricular tachycar-
ia) occurred in the exercise ECG recommended before
ospital discharge. In all other patients, coronary angiog-
aphy as a routine assessment after successful thrombol-
sis was encouraged within 2 to 4 weeks after discharge.
Beta-blockers and statins were administered to all
atients unless contraindicated, angiotensin-converting
nzyme inhibitors when indicated. Patients receiving
tents were recommended clopidogrel 75 mg daily for 9
onths. The other patients were recommended clopi-
ogrel until angiography was performed or for 9 months,
t the discretion of the treating physician. Complete
linical follow-up was performed at 3 and 12 months, and
elephone follow-up was performed at 1 and 7 months.
roponin-T levels were measured in all patients the third
orning after onset of STEMI, and myocardial perfusion
ingle-photon emission computed tomography (SPECT)
Abbreviations
and Acronyms
CI  confidence interval
ECG  electrocardiogram
HR  hazard ratio
IQR  interquartile range
PCI  percutaneous
coronary intervention
SPECT  single-photon
emission computed
tomography
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionas scheduled after 3 months.
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Management of Acute Myocardial Infarction in Rural Areas January 12, 2010:102–10nd points and definitions. The primary end point was a
omposite of death, reinfarction, stroke, or new myocar-
ial ischemia at 12 months. Reinfarction in the first 18 h
as defined as recurrent symptoms of ischemia at rest
ccompanied by new ST-segment elevation of 0.1 mV
n at least 2 contiguous leads, lasting 30 min. After
8 h, the definition was: new Q waves in 2 or more leads,
r new increase in concentrations of creatine kinase-MB
r troponins above the upper limit of normal (3 upper
imit of normal after PCI and 5 upper limit of normal
fter coronary artery bypass graft), and 50% higher than
he previous value. Stroke was defined as a new focal,
eurological deficit of vascular origin lasting more than
4 h. New myocardial ischemia was defined as unstable
ngina (chest pain at rest suspicious for coronary disease
ith or without ECG changes), recurrent angina grade II to
V (Canadian Cardiovascular Society classification) or seri-
us arrhythmias (ventricular tachycardia/ventricular fibrilla-
ion) that appeared more than 12 h after randomization.
The secondary end points included a composite of death,
troke, or reinfarction at 12 months, transport-related com-
lications, bleeding at 30 days, and infarct size. Bleeding
omplications were classified according to the GUSTO
Global Use of Strategies To Open coronary arteries) severity
cale (10). Infarct size was assessed by SPECT (11,12), and
y troponin T levels (13,14).
A blinded, independent Clinical Event Committee adju-
icated all possible events related to the primary outcome.
he SPECT analysis and processing of recordings and the
valuation of all angiograms were performed by people
naware of the clinical data and treatment allocation. An
ndependent monitor verified a random sample of 20% of
he patient data entry into the case-report forms against the
atient’s medical records.
tatistical analysis. On the basis of previous reports (3–5),
e anticipated that the occurrence of the primary end point
ould be 30% in the conservative group and 15% in the
arly invasive group. With a 2-sided alpha of 5% and a
ower of 80%, a total of 266 patients were required.
tatistical analyses were performed according to the
ntention-to-treat principle. Continuous variables were ex-
ressed as median with interquartile range (IQR) or mean 
D, and compared between groups using the Mann-
hitney U test or 2-sample t tests, respectively. Cate-
orical variables were expressed as frequency (percentage)
nd compared using the chi-square test with Yates
orrection or Fisher exact test, as appropriate. Estimation
f the cumulative primary event rate was performed with
he Kaplan-Meier method, and events over time were
ompared using the log rank test. The Cox proportional
azards model was used to estimate the treatment effect
s unadjusted hazard ratio (HR) with 95% confidence
ntervals (CIs). A 2-sided value of p  0.05 was consid-
red significant. Patient data and analysis results were
anaged in a database/analysis program (Epi Data/Epi mnfo version 3.4.3, 2007, Centers for Disease Control and
revention, Atlanta, Georgia).
esults
aseline characteristics. During the enrollment period,
24 patients were treated with thrombolysis for STEMI
nd screened for participation in the study, and 276
atients (53%) were subsequently included (Fig. 1). Ten
atients were secondarily excluded because of violation of
nclusion or exclusion criteria. Thus, 134 patients were
eft to follow-up in the early invasive and 132 in the
onservative group. With the exception of 2 patients with
ery short time to treatment, all included patients had
heir STEMI diagnosis supported by increase of troponin
oncentrations above the upper limit of normal. In the
onservative group, there was a higher prevalence of
ypertension and a higher heart rate at randomization.
therwise, the baseline characteristics were well balanced
etween the groups (Table 2).
reatment received. Among all, 57% received thrombol-
sis in the pre-hospital setting, and time delay from symp-
om onset to thrombolysis was 123 min (IQR 80 to 195
in). Invasive procedures performed in the 2 groups are
escribed in Table 3. Most patients in both groups were
eferred to coronary angiography, but the procedure was
elayed by a median time of 5.5 days in the conservative
ompared with the early invasive group. The total number
f PCI procedures was significantly higher in the early
nvasive group. In contrast, the number of coronary bypass
rafts was higher in the conservative group (p  NS).
In the conservative group, 36 patients (27%) were trans-
erred for rescue coronary intervention, and 32 patients
nderwent rescue PCI. Distances, delays, and Thrombolysis
n Myocardial Infarction (TIMI) flow grade in this rescue
roup, compared with the early invasive group, are pre-
ented in Table 4. The rescue group had their PCI per-
ormed significantly later than the early invasive group, but
o differences in the rate of TIMI flow grade 3 were
bserved, neither before nor after PCI (Table 4). Of the
emaining 96 patients, 89 underwent angiography at a
edian time of 11 days (IQR 3 to 23 days) after random-
zation, and PCI was performed in 62 patients (65%); TIMI
ow grade 3 was found in 77 of these patients (87%) before
ntervention.
At discharge, 98% of patients were prescribed aspirin,
2% clopidogrel, 90% beta-blockers, and 99% statins, with
o difference between groups. The use of agents acting on
he renin-angiotensin system was higher in the conservative
60%) compared with the invasive (42%) group. At 1 year,
edication was unchanged except for clopidogrel, which
as used in only 21% of patients (no difference between
roups). At 7 months, 83% of patients were still taking
lopidogrel.
linical outcome. The clinical outcomes at 30 days and 12
onths are listed in Table 5. The primary end point at 12
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January 12, 2010:102–10 Management of Acute Myocardial Infarction in Rural Areasonths occurred in 28 patients (21%) in the early invasive
roup and in 36 patients (27%) in the conservative group
HR: 0.72, 95% CI: 0.44 to 1.18, p  0.19) (Fig. 2A). The
econdary composite end point of death, stroke, or reinfarc-
ion at 12 months occurred in 8 patients (6%) in the early
nvasive group and in 21 patients (16%) in the conservative
roup (HR: 0.36, 95% CI: 0.16 to 0.81, p 0.01) (Fig. 2B).
he overall mortality was 2.6%. The causes of death were
ardiogenic shock (n 3), intracranial hemorrhage (n 2),
erebral infarction (n  1), and cancer (n  1).
At 30 days, the combined incidence of death, reinfarc-
ion, stroke, or new ischemia was significantly reduced in
he early invasive compared with the conservative group
10% vs. 21%, relative risk: 0.49, 95% CI: 0.27 to 0.89, p 
.03). The incidence of the secondary composite end point
t 30 days was also lower in the invasive group (4.5% vs.
.8%, relative risk: 0.45, 95% CI: 0.18 to 1.16, p  0.14).
No significant difference was observed in risk of
Figure 1 Study Flow Chart
ECG  electrocardiogram; PCI  percutaneous coronary intervention.leeding between the 2 groups (Table 6). Only 2 patients v0.8%) received blood transfusion. All severe bleedings
ere caused by intracranial hemorrhages. In these 5
atients (1.9%), onset of symptoms was 12 h after
hrombolysis.
The transfer distances from first medical contact to the
CI center were long, with a median distance of 158 km
IQR 129 to 200 km) in the early invasive group (Table 4).
ne patient (0.7%) died during transfer, and 4 (3%) were
uccessfully defibrillated in the early invasive group. In the
onservative group, 2 patients had ventricular tachycardia
reated with intravenous drugs.
nfarct size. After 3 months, SPECT with determination
f infarct size was performed in 125 (93%) patients in the
arly invasive and 120 patients (91%) in the conservative
roup. Eighty-two patients (34%) had no signs of infarc-
ion. Median infarct size, estimated as percent of the left
entricle, was 7% (IQR 0% to 24%) in the early invasive
roup compared with 6% (IQR 0% to 19%) in the conser-
ative group (p  0.29). Furthermore, no significant differ-
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Management of Acute Myocardial Infarction in Rural Areas January 12, 2010:102–10nce in third-day troponin-T concentration was found
etween the early invasive (n  126) and the conservative
roup (n 130) (1.75 g/l [IQR 0.86 to 2.92 g/l] vs. 2.08
g/l [IQR 0.78 to 3.97 g/l], p  0.38).
Baseline Characteristics at RandomizationTable 2 Baseline Characteristics at Random
Ea
Age (yrs)
Men
Body mass index (kg/m2)
Total cholesterol (mmol/l)
Treated hypertension
Diabetes mellitus
Current or previous smoker
Family history of coronary heart disease
Previous angina
Previous myocardial infarction
Previous coronary bypass graft
Previous angioplasty
Infarct location on ECG
Anterior
New left bundle branch block
Nonanterior
Blood pressure before thrombolysis (mm Hg)
Systolic 1
Diastolic
Heart rate (beats/min)
Time intervals (min)
Symptom onset to first medical contact
Symptom onset to tenecteplase
Pre-hospital tenecteplase
Data are median (25th, 75th percentiles), mean (SD), or n (%).
ECG  electrocardiogram; RAS  renin-angiotensin system.
Invasive Procedures in the 2 Randomization GroTable 3 Invasive Procedures in the 2 Rando
Early Inva
(n 
Coronary angiography performed 133 (99%
Time from TNK to arrival at
catheterization laboratory
130 (105
Angiography within 3 h of TNK 111 (83%
Angiography within 12 h of TNK 133 (99%
Angiography within 30 days 133 (99%
PCI performed 119 (89%
Time from TNK to first balloon 163 (137
Radial access 111 (83%
Stents implanted 115 (86%
Bare-metal stents 111 (83%
Drug-eluting stents 4 (3%)
Abciximab 16 (14%
Thrombectomy 0 (0%)
Intra-aortic balloon pump 2 (1.5%
CABG performed 9 (7%)
CABG within 7 days 2 (1.5%
Repeat angiography during follow-up 23 (17%
Repeat PCI during follow-up 15 (11%Data are n (%) or median (25th, 75th percentiles).
CABG  coronary artery bypass graft; PCI  percutaneous coronary interveiscussion
ven the best-organized networks between ambulance ser-
ice, community hospitals, and PCI centers cannot make
on
asive Group
134)
Conservative Group
(n  132) p Value
55, 67) 61 (53, 68) 0.98
80%) 94 (71%) 0.13
24.7, 30.0) 26.4 (24.1, 30.0) 0.21
1.1) 5.4 (1.1) 0.11
25%) 50 (38%) 0.03
6%) 10 (8%) 0.78
79%) 104 (79%) 0.93
58%) 78 (59%) 0.88
13%) 17 (13%) 0.89
11%) 14 (11%) 0.97
3%) 3 (2%) 1.0
7%) 12 (9%) 0.62
44%) 51 (39%) 0.44
3%) 0 (0%) 0.12
53%) 81 (61%) 0.21
22.9) 134.2 (22.4) 0.74
15.2) 82.0 (15.9) 0.48
14.6) 70.7 (17.6) 0.02
34, 122) 65 (40, 135) 0.68
80, 195) 126 (80, 195) 0.72
60%) 71 (54%) 0.40
tion Groups
roup Conservative Group
(n  132) p Value
125 (95%) 0.04
min 5.5 (0, 17.5) days 0.001
16 (12%) 0.001
43 (33%) 0.001
114 (86%) 0.001
94 (71%) 0.001
min 3.0 (0, 13) days 0.001
118 (89%) 0.17
90 (68%) 0.001
80 (61%) 0.001
10 (8%) 0.16
8 (6%) 0.14
1 (0.8%) 0.5
2 (1.5%) 1.0
16 (12%) 0.19
0 (0%) 0.50
17 (13%) 0.42
9 (7%) 0.30izati
rly Inv
(n 
60 (
107 (
26.5 (
5.2 (
33 (
8 (
106 (
77 (
17 (
15 (
4 (
9 (
59 (
4 (
71 (
33.4 (
80.7 (
65.3 (
67 (
117 (
80 (upsmiza
sive G
134)
)
, 155)
)
)
)
)
, 191)
)
)
)
)
)
)
)
)ntion; TNK  tenecteplase.
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January 12, 2010:102–10 Management of Acute Myocardial Infarction in Rural Areasrimary PCI available in a timely manner to all patients with
TEMI. The NORDISTEMI study was designed to assess
he optimal treatment for patients with STEMI living in
ural areas where thrombolysis is the primary revasculariza-
ion therapy. The effect of early invasive treatment after
hrombolysis in areas with very long transfer distances have
ot been evaluated previously.
In the NORDISTEMI study, the median transfer distance
o PCI was 158 km, and the median transfer time was 130
linical Outcomes at 30 Days and 12 MonthsTable 5 Clinical Outcomes at 30 Days and 12 Months
Early Invasive Group
(n  134)
Conservative Group
(n  132)
At 30 days
Death, reinfarction, stroke,
or new ischemia
14 (10.0%) 28 (21.2%)
Death, reinfarction, or stroke 6 (4.5%) 13 (9.8%)
Death 3 (2.2%) 3 (2.3%)
Reinfarction 2 (1.5%) 7 (5.3%)
Stroke 3 (2.2%) 5 (3.8%)
Recurrent ischemia 8 (6.0%) 16 (12.1%)
At 12 months
Death, reinfarction, stroke,
or new ischemia
28 (20.9%) 36 (27.3%)
Death, reinfarction, or stroke 8 (6.0%) 21 (15.9%)
Death 3 (2.2%) 4 (3.0%)
Reinfarction 4 (3.0%) 12 (9.1%)
Stroke 3 (2.2%) 7 (5.3%)
Recurrent ischemia 20 (15.0%) 20 (15.2%)
ransfer Distances, Time Intervals, and Angiographic Characteristicf the Early Invasive Group and the Rescue Population of the ConsTable 4 Transfer Dista ces, Time Intervals, and Angiograph c Cof the Early Invasive Group and the Rescue Population
Transport distance from first medical contact to PCI center (km)
Time from tenecteplase to arrival at catheterization laboratory (min)
Immediate/rescue PCI performed
Time from tenecteplase to first balloon (min)
Symptom onset to first balloon (min)
Infarct-related artery
Left anterior descending artery
Left circumflex artery
Right coronary artery
Graft
Not identified
TIMI flow grade pre-PCI
0
1
2
3
TIMI flow grade post-PCI
0
1
2
3
ata are median (25th, 75th percentiles) or n (%).
PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.oata are n (%).in. The early invasive strategy was associated with a reduction
n the primary end point at 12 months compared with a
onservative strategy, but the reduction did not reach statistical
ignificance. Recent trials evaluating the effect of early angio-
lasty after thrombolysis, including the recent TRANSFER-
MI (Trial of Routine Angioplasty and Stenting after Fibri-
olysis to Enhance Reperfusion in Acute Myocardial
nfarction) study (15), have reported a significantly improved
utcome with an early invasive strategy (3–7,15,16). Timing of
CI after thrombolysis, control-group interventions, and def-
nitions of end points have varied considerably among these
rials and might contribute to this discrepancy. Furthermore, it
hould be noted that at 30 days, the composite of death,
einfarction, stroke, and new ischemia was significantly re-
uced in the invasive group, in accordance with previous trials
relative risk: 0.49, p  0.03).
Both in our study and in the TRANSFER-AMI trial
15), an antithrombotic regimen including enoxaparin
nd clopidogrel was given in addition to full-dose tenecte-
lase. The early addition of clopidogrel to aspirin and
brinolytic treatment has been shown to reduce the risk of
ardiac events (9,17), but has not been used in previous trials
nvestigating the effect of early PCI after thrombolysis.
Compared with most previous studies (3,4,7), a more
iberal referral for angiography in the conservative group
as allowed, and 95% of patients underwent angiography
t a medium time of 5.5 days after thrombolysis. This
ore aggressive treatment of the conservative group in
ive Groupcteristics
e Conservative Group
nvasive Group
 134)
Conservative/Rescue Group
(n  36) p Value
(129, 200) 180 (132, 234) 0.39
(105, 155) 187 (149, 240) 0.001
(88%) 32 (89%) 1.0
(137, 189) 209 (193, 247) 0.001
(236, 380) 340 (279, 400) 0.04
(47%) 19 (53%) 0.61
(9%) 0 (0%) 0.07
(41%) 15 (42%) 0.90
(2%) 1 (3%) 1.0
(1%) 1 (3%) 0.38
n  133) (n  36)
(13%) 9 (25%) 0.12
(8%) 2 (6%) 1.0
(29%) 8 (22%) 0.54
(50%) 17 (47%) 0.91
n  118) (n  32)
(2%) 1 (3%) 0.52
(2%) 0 (0%) 1.0
(9%) 3 (9%) 1.0
(87%) 28 (88%) 1.0servathara
of th
Early I
(n
158
130
118
162
302
62
12
55
3
1
(
17
10
39
67
(
2
2
11
103ur study, with liberal referral to coronary angiography
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Management of Acute Myocardial Infarction in Rural Areas January 12, 2010:102–10nd early addition of clopidogrel, has probably reduced
he difference between groups at 12 months. Further-
ore, no high-risk characteristics were demanded for
nclusion in our study. This benign risk profile of the
ohort may have prevented the demonstration of a more
ignificant benefit.
The risk reduction associated with an early invasive
trategy in previous studies has mainly been attributed to
Figure 2 Kaplan-Meier Curves
Kaplan-Meier curves for (A) the primary outcome (composite of death, reinfarctioneductions in reinfarction or recurrent ischemia. Our study gas not powered to look at individual end points. However,
he rate of new ischemia was numerically similar in both
roups. New ischemia was approved as an end point without
CG changes, and this soft definition might have resulted
n misclassification of some events. Therefore, the secondary
omposite end point of death, reinfarction, and stroke at
2 months should be noted, being significantly reduced in
he early invasive group compared with the conservative
e, or new ischemia) and (B) the composite of death, stroke, or reinfarction., strokroup (HR: 0.36, p  0.01).
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January 12, 2010:102–10 Management of Acute Myocardial Infarction in Rural AreasThe rate of bleeding was low and did not differ between
roups. Use of radial approach in 86% of patients together
ith limited use of glycoprotein IIb/IIIa inhibitors (9%)
ere probably the main reasons for the low number of
USTO minor and moderate bleedings (18). The rate of
USTO severe bleeding was as reported in other trials
1.9%); however, the rate of intracranial hemorrhage was
igher than expected (19). The heavy loading of patients
ith antithrombotic drugs might be of concern, but recent
nalysis has not shown any increase in intracranial hemor-
hages when adding enoxaparin and clopidogrel to fibrino-
ytic treatment (20).
Trials such as the NORDISTEMI study, in which PCI
s performed a few hours after fibrinolysis, are different from
he approach of performing PCI immediately after fibrino-
ysis (facilitated PCI), which has been associated with no
linical benefit compared with primary PCI (21,22). The
ime between fibrinolysis and PCI might have been too
hort in these studies (90 to 104 min).
The optimal time window for early PCI after fibrinolysis
s unsettled. Five recent studies investigating the effect of
arly PCI after fibrinolysis had intervals from fibrinolysis to
CI ranging from 2 to 17 h (3–5,7,15). In our study, the
edian time from fibrinolysis to PCI was 163 min (2.7 h)
n the early invasive group. Although short delays, the
ncidence of death, reinfarction, or stroke at 30 days was low
4.5%). We might speculate that the antithrombotic co-
herapy used in our study has mitigated the early thrombotic
omplications observed in the ASSENT-4 (Assessment of
he Safety and Efficacy of a New Treatment Strategy with
ercutaneous Coronary Intervention) trial (21), and that
his antithrombotic regimen together with use of a radial
pproach, might allow a shorter time between fibrinolysis
nd PCI.
Information about the risk of adverse events during
ransfer of STEMI patients has mostly come from studies
omparing transfer for primary PCI to local thrombolysis
1). Although considerably longer transfer distances in the
ORDISTEMI study, the occurrence of transfer compli-
ations in the early invasive group was consistent with
revious results.
The median infarct sizes determined by SPECT at
months were small and did not differ significantly between
roups. One-third of patients had no visible infarctions at
0-Day Bleeding Events (GUSTO Classification)Table 6 30-Day Bleeding Events (GUSTO Classification)
Early Invasive Group
(n  134)
Conservative Group
(n  132) p Value
Severe bleeding,
including ICH
2 3
Moderate bleeding 0 3
Minor bleeding 14 13
All 16 (12%) 19 (14%) 0.68
ata are n or n (%).
GUSTO  Global Use of Strategies To Open coronary arteries; ICH  intracranial hemorrhage.PECT. The very short median time of 123 min from aymptom onset to fibrinolysis, with 25% of patients treated
ithin 80 min, might contribute to this high percentage of
nvisible infarctions (23). A previous trial has reported
maller infarct sizes with early angioplasty compared with
onventional care after thrombolysis (24). Because of the
ong transfer distances in the NORDISTEMI study, me-
ian time from symptom onset to first balloon was 5 h in the
arly invasive group, being beyond the time limit for major
yocardial salvage (25).
Both the small infarct sizes and the low 1-year mortality
2.6%) might reflect the short time to treatment obtained by
eans of a well-organized system for pre-hospital throm-
olysis (26,27). Our study indicates a potential for improv-
ng reperfusion strategies for patients living in rural areas
ith long transfer distances to PCI. This may be achieved
y applying a well-organized pharmacoinvasive approach
ncluding pre-hospital thrombolysis and rapid transfer to an
nvasive center.
tudy limitations. This study was powered only to detect
ifferences in the primary composite end point, but not for
he individual components of the end point or for safety.
ecause of the design of the trial, infarct size was not
ssessed in the acute phase. The open-label design might
ave introduced some bias. However, the clinical end points
ere adjudicated by an event committee blinded to the
llocated treatment, and infarct size was assessed without
nowledge of treatment assignment.
Unfortunately, randomization was not entirely successful
n producing balanced groups. It cannot be ruled out that
he small imbalance might have had some confounding
ffect on the outcome.
The study did not question the superiority of timely
rimary PCI over thrombolysis. At the time when the
ORDISTEMI study was initiated, transfer for primary
CI in areas with more than 2-h delays was not an option
ecause of ethical reasons.
According to the inclusion and exclusion criteria, the
onclusions of the study are applicable only to STEMI
atients age 76 years with symptom onset 6 h, without
ardiogenic shock at randomization and with long transfer
elays to primary PCI.
onclusions
lthough the study did not show any significant reduction
n the primary outcome at 12 months, the significant
eduction in the composite of death, reinfarction, or stroke
uggests that an early invasive strategy may be the preferred
ption in patients receiving thrombolytic therapy, also in
reas with long transfer distances. These findings might be
aken into consideration when making algorithms for treat-
ent of STEMI in rural areas.
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